Navigation Links
Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
Date:10/21/2013

SAN DIEGO, Oct. 21, 2013 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of rare orphan diseases, today announced it has secured $5 million in a Series A funding round led by multiple private capital, high net-worth investors from Canada, Japan and the United States.

(Logo: http://photos.prnewswire.com/prnh/20130531/MM24393LOGO)

The Series A funding, which comprised more than 90% of the Series Seed investors, will enable Arcturus to maintain its momentum, nominate its first clinical candidate in 2014, and recruit high caliber talent to expand its operations at the respected Janssen Labs in La Jolla, Calif.

Arcturus anticipates additional revenues in 2014 from its portfolio of Unlocked Nucleic Acid (UNA) intellectual property, wherein very broad claims were recently granted by the USPTO). Furthermore, Arcturus' best-in-class delivery technology will also contribute to the company's ability to nominate additional clinical candidates throughout 2014 as the organization expands its pipeline and brings RNAi technologies to a new level.  

"As we meet with investors and potential partners, we're excited to share with them the progress we've made," said Pad Chivukula, co-founder and chief operating officer, Arcturus. "We are leading development of the next wave of best-in-class RNAi technologies that promises to improve the quality of life and our world, and are proud to have the financial support and trust of our investors along with the respect of our peers."

"Now is the time for large pharmaceutical companies who have been on the sidelines to enter the RNAi market," said Joseph E. Payne, president and CEO, Arcturus. "We are leading the way in pioneering disruptive advances in this space that will truly impact many people and be a game-changer within the medical field."

Arcturus management is fully committed to the commercialization of new pharmaceuticals through the combination of in-house discovery and development, pharmaceutical partnerships and licensed commercial rights.

About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Calif., Arcturus Therapeutics is poised to become an industry leader in the application of RNAi technologies for the treatment of disease and improved quality of life. The company's aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of therapeutic modalities, Arcturus is on the forefront of research and development of nanoparticle siRNA drug delivery systems. The company is located in San Diego-based Janssen Labs – where disruptive research is underway by some of today's leading scientists and up-and-coming technologists who are working side-by-side to develop pioneering medical treatments. For more information, visit us at www.ArcturusRx.com.


'/>"/>
SOURCE Arcturus Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
2. Drug development venture links translational research, business to launch new therapeutics
3. UCLA scientists develop new therapeutics that could accelerate wound healing
4. FASEB SRC announces conference registration open for: Melatonin Biology: Actions & Therapeutics
5. NTU launches new centre to develop new eye-deas for occular therapeutics
6. Fred Hutchinson Cancer Research Center partners with GlaxoSmithKline to develop muscular dystrophy therapeutics
7. Magical state of embryonic stem cells may help overcome hurdles to therapeutics
8. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
9. Study of oceans past raises worries about their future
10. Identification of stem cells raises possibility of new therapies
11. New Geology study raises questions about long-held theories of human evolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2020)... ... August 19, 2020 , ... ... and SalivaBio LLC, businesses dedicated to Salivary Bioscience for more than twenty years. ... published book by Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva Research and ...
(Date:8/7/2020)... , ... August 06, 2020 , ... ... industry, is pleased to announce that Eric Chen and Jessica Wong have joined ... Product Management & Strategy, respectively. , Eric Chen heads development efforts for Alucio’s ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin ... portfolio with a near term focus on Type 2 diabetes and associated comorbidities. ... across multiple therapeutic areas and classes. As Chief Commercial Officer, Justin will lead ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... Mass. and SOMERSET, N.J (PRWEB) , ... July ... ... leading genome editing company, and Catalent, the leading global provider of advanced delivery ... consumer health products, today announced that they have entered into a strategic partnership ...
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® ... in 16 countries, has reached its 20th anniversary of worldwide use. Introduced in ... at top universities including University of Pennsylvania, University of Michigan, University of Maryland, ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed ... Manager Regulatory Solutions, in a one hour live webinar on Thursday, August ... in China for drugs and medical devices. Specifically, for medical devices, the NMPA has ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this ... the only technology of its kind on the market and we were pleased that ... protective capacity of traditional cultured ingredients, creating a natural way to extend the shelf ...
Breaking Biology Technology: